Boston Scientific Corp.
Income Statement
| Line Item | FY2009 | FY2008 | FY2007 |
|---|---|---|---|
| Revenue | $8.19B | $8.05B | $8.36B |
| Endoscopy | — | — | — |
| Urology | — | — | — |
| Neuromodulation | — | — | — |
| Cardiac Rhythm Management | — | — | — |
| Electrophysiology | — | — | — |
| Interventional Cardiology | — | — | — |
| Peripheral Interventions | — | — | — |
| Watchman | — | — | — |
| Interventional Cardiology & Vascular Therapies | — | — | — |
| Interventional Oncology & Embolization | — | — | — |
| Specialty Pharmaceuticals/Other | — | — | — |
| Cost of Revenue | $2.58B | $2.47B | $2.34B |
| Gross Profit | $5.61B | $5.58B | $6.02B |
| Gross Margin | 68.5% | 69.3% | 72.0% |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | $2.64B | $2.59B | $2.91B |
| Operating Income | $-894.0M | $-1.51B | $-14.0M |
| Operating Margin | -10.9% | -18.7% | -0.2% |
| Interest Expense | $407.0M | $468.0M | $570.0M |
| Pretax Income | $-1.31B | $-2.03B | $-569.0M |
| Income Tax Expense | $-283.0M | $5.0M | $-74.0M |
| Net Income | $-1.03B | $-2.04B | $-495.0M |
| Net Margin | -12.5% | -25.3% | -5.9% |
| EPS (Basic) | $-0.68 | $-1.36 | $-0.33 |
| EPS (Diluted) | $-0.68 | $-1.36 | $-0.33 |
| Shares Outstanding (Basic) | 1.51B | 1.50B | 1.49B |
| Shares Outstanding (Diluted) | 1.51B | 1.50B | 1.49B |
| Dividends Per Share | — | — | — |